Aspen Pharmacare has posted a 33% decline in HEPS for the six months to December, citing one-off restructuring costs of R69m incurred in the local and French sterile manufacturing facilities. Business Day TV spoke to Sean Capazorio, Group CFO at Aspen, for more insight.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.